| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Multiple myeloma (MM) is a hematological malignancy with a very heterogenous presentation, course and prognosis. Despite an immense progress in the understanding of the tumour biology, neoplastic transformation and progression, we still do not know all the processes that contribute to the multistep pathogenesis of this disease. {/p}{p} For quite a long time there have been a lot of efforts at the improvement of therapeutic approaches in order to intensify the treatment to reach a better response rate, and to prolong the overall survival in MM patients. For more than 30 years, combined chemotherapeutic regimens, and later on high-dosed regimens with autologous stem cell transplantation tried to establish the best approach, however, none of the conventional regimens finally turned out to be significantly superior than the regimen MP (melphallan and prednisone) in the elderly, and HD-ASCT (high-dosed chemotherapy with support of autologous stem cell transplantation) in younger patients. {/p}{p} The last 10 years, however, dramatically changed therapeutic outcomes, and the long lasting %22golden-standard%22 treatment schedules were modified substantially. This change was caused by the introduction of the first generation of novel drugs with %22biological mechanism of action%22. These new drugs are thalidomide, bortezomib and lenalidomide. {/p}{p} Thalidomide, this teratogenic agent whose short sad history started in 1950's and ended in 1961 was re-discovered for multiple myeloma in 1999. Since then, several randomized studies have confirmed its superiority in the treatment of relapsed and refractory MM as well as in the frontline treatment of the disease.
- Multiple myeloma (MM) is a hematological malignancy with a very heterogenous presentation, course and prognosis. Despite an immense progress in the understanding of the tumour biology, neoplastic transformation and progression, we still do not know all the processes that contribute to the multistep pathogenesis of this disease. {/p}{p} For quite a long time there have been a lot of efforts at the improvement of therapeutic approaches in order to intensify the treatment to reach a better response rate, and to prolong the overall survival in MM patients. For more than 30 years, combined chemotherapeutic regimens, and later on high-dosed regimens with autologous stem cell transplantation tried to establish the best approach, however, none of the conventional regimens finally turned out to be significantly superior than the regimen MP (melphallan and prednisone) in the elderly, and HD-ASCT (high-dosed chemotherapy with support of autologous stem cell transplantation) in younger patients. {/p}{p} The last 10 years, however, dramatically changed therapeutic outcomes, and the long lasting %22golden-standard%22 treatment schedules were modified substantially. This change was caused by the introduction of the first generation of novel drugs with %22biological mechanism of action%22. These new drugs are thalidomide, bortezomib and lenalidomide. {/p}{p} Thalidomide, this teratogenic agent whose short sad history started in 1950's and ended in 1961 was re-discovered for multiple myeloma in 1999. Since then, several randomized studies have confirmed its superiority in the treatment of relapsed and refractory MM as well as in the frontline treatment of the disease. (en)
|
| Title
| - Thalidomide, Bortezomib and Lenalidomide - Three Drugs that Changed Multiple Myeloma
- Thalidomide, Bortezomib and Lenalidomide - Three Drugs that Changed Multiple Myeloma (en)
|
| skos:prefLabel
| - Thalidomide, Bortezomib and Lenalidomide - Three Drugs that Changed Multiple Myeloma
- Thalidomide, Bortezomib and Lenalidomide - Three Drugs that Changed Multiple Myeloma (en)
|
| skos:notation
| - RIV/61989592:15110/14:33151199!RIV15-MSM-15110___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/14:33151199
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - Multiple Myeloma; Lenalidomide; Bortezomib; Thalidomide (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/mistoVydani
| |
| http://linked.open...vEdiceCisloSvazku
| |
| http://linked.open...i/riv/nazevZdroje
| - Frontiers in Clinical Drug Research-Hematology
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...v/pocetStranKnihy
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...iv/tvurceVysledku
| - Ščudla, Vlastimil
- Minařík, Jiří
|
| number of pages
| |
| http://purl.org/ne...btex#hasPublisher
| |
| https://schema.org/isbn
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)